Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296363 | 1.00 | SLC18A3 (0.34) | SLC18A3L3MBTL1PDCD1CD274DPP4 | |
| SCHEMBL4286142 | 0.88 | HDAC8 (0.36) | SLC18A3CYP2D6CYP3A4CYP2C9KCNH2 | |
| SCHEMBL4286141 | 0.88 | HDAC8 (0.36) | SLC18A3CYP2D6CYP3A4CYP2C9KCNH2 | |
| SCHEMBL4284624 | 0.79 | CA1 (0.41) | SLC18A3DPP4DPP7CYP2D6EGFR | |
| SCHEMBL4284825 | 0.77 | CA1 (0.37) | SLC18A3L3MBTL1CYP2D6CHRM1CYP3A4 | |
| SCHEMBL4284827 | 0.77 | CA1 (0.37) | SLC18A3L3MBTL1CYP2D6CHRM1CYP3A4 | |
| SCHEMBL13705146 | 0.77 | CA1 (0.37) | SLC18A3L3MBTL1CYP2D6CHRM1CYP3A4 | |
| SCHEMBL4284830 | 0.77 | CA1 (0.37) | SLC18A3L3MBTL1CYP2D6CHRM1CYP3A4 | |
| SCHEMBL4281674 | 0.76 | L3MBTL1 (0.47) | L3MBTL1DPP4DPP7MAOAMAOB | |
| SCHEMBL4281677 | 0.76 | L3MBTL1 (0.47) | L3MBTL1DPP4DPP7MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SLC18A3 2243/4885L3MBTL1 3597/4885PDCD1 3380/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | SLC18A3 2243/4885L3MBTL1 3597/4885PDCD1 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.